Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008
FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.
FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.